Relmada Therapeutics, Inc. (RLMD) - What Are Investment Firms Thinking About This Stock?

Key Points

• Analysts remain moderately bullish: Eight analysts give Relmada Therapeutics an average “Moderate Buy” rating, with a consensus 12-month price target of $12 versus the stock’s recent price of $3.58. However, Weiss Ratings maintains a “sell (D-)” assessment.
• Insider and institutional ownership show continued interest: CFO Maged Shenouda bought 79,800 shares at $4.25 each, increasing his stake by 8.67%; insiders own 14.50% and institutional investors hold 45.24% of the stock.
• Relmada remains a loss-making clinical-stage biotech: The company is developing REL-1017 for treatment-resistant major depressive disorder and recently reported a quarterly loss of $0.11 per share, better than the $0.20 analyst consensus. Analysts expect a full-year loss of $0.62 per share.

Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) have received an average rating of "Moderate Buy" from the eight analysts that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $12.00.

Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Relmada Therapeutics in a research report on Monday, September 14th.

Insider Activity at Relmada Therapeutics

In related news, CFO Maged Shenouda purchased 79,800 shares of the firm's stock in a transaction that occurred on Thursday, September 10th. The stock was acquired at an average price of $4.25 per share, for a total transaction of $339,150.00. Following the transaction, the chief financial officer directly owned 1,000,000 shares of the company's stock, valued at $4,250,000. This trade represents a 8.67% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 14.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Relmada Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of RLMD. Legal & General Group Plc purchased a new stake in shares of Relmada Therapeutics in the 2nd quarter valued at approximately $64,000. AXQ Capital LP acquired a new position in Relmada Therapeutics in the 2nd quarter worth approximately $84,000. State of Wyoming acquired a new position in Relmada Therapeutics in the 1st quarter worth approximately $88,000. Keebeck Wealth Management purchased a new position in Relmada Therapeutics during the 1st quarter worth approximately $90,000. Finally, The Manufacturers Life Insurance Company purchased a new position in Relmada Therapeutics during the 2nd quarter worth approximately $173,000. Institutional investors and hedge funds own 45.24% of the company's stock.

Relmada Therapeutics Stock Performance

Relmada Therapeutics stock opened at $3.58 on Friday. The firm has a market cap of $381.88 million, a price-to-earnings ratio of -3.98 and a beta of 0.51. Relmada Therapeutics has a 1 year low of $2.15 and a 1 year high of $8.00. The firm's 50 day moving average price is $3.84 and its two-hundred day moving average price is $5.32.

Relmada Therapeutics (NASDAQ:RLMD - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.20) by $0.09. As a group, equities analysts predict that Relmada Therapeutics will post -0.62 EPS for the current fiscal year.

About Relmada Therapeutics

Relmada Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for central nervous system disorders. The company's research has primarily targeted conditions with significant unmet medical needs, including major depressive disorder and other neuropsychiatric diseases.

Relmada's lead investigational product is REL-1017, also known as esmethadone or dextromethadone. The orally administered compound is designed to modulate the N-methyl-D-aspartate (NMDA) receptor and has been studied as a potential adjunctive treatment for major depressive disorder in patients who do not respond adequately to standard antidepressants.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.